Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Toxoplasmosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H2 2016, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape. Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.Toxoplasmosis. Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Toxoplasmosis Overview 6 Therapeutics Development 7 Pipeline Products for Toxoplasmosis - Overview 7 Pipeline Products for Toxoplasmosis - Comparative Analysis 8 Toxoplasmosis - Therapeutics under Development by Companies 9 Toxoplasmosis - Therapeutics under Investigation by Universities/Institutes 10 Toxoplasmosis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Toxoplasmosis - Products under Development by Companies 13 Toxoplasmosis - Products under Investigation by Universities/Institutes 14 Toxoplasmosis - Companies Involved in Therapeutics Development 15 AbbVie Inc 15 Turing Pharmaceuticals AG 16 Toxoplasmosis - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 23 Drug Profiles 25 CCP-010 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecules for Toxoplasmosis - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit DHFR for Toxoplasmosis - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 toxoplasmosis vaccine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 toxoplasmosis vaccine - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 toxoplasmosis vaccine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 toxoplasmosis vaccine - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 TRP-004 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 TRP-012 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 TRP-013 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Toxoplasmosis - Dormant Projects 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Toxoplasmosis, H2 2016 7 Number of Products under Development for Toxoplasmosis - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Toxoplasmosis - Pipeline by AbbVie Inc, H2 2016 15 Toxoplasmosis - Pipeline by Turing Pharmaceuticals AG, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Stage and Target, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 24 Toxoplasmosis - Dormant Projects, H2 2016 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.